SCHEMBL19328352

SCHEMBL19328352

Cc1ccc(C(=O)C(Br)CC(=O)O)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.47
ALDH1A1 P00352 4/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
GSK3B P49841 1/20 0.46
LMNA P02545 3/20 0.43
CES2 O00748 2/20 0.43
CES1 P23141 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
SRD5A2 P31213 2/20 0.42
MAPT P10636 1/20 0.41
FFAR1 O14842 1/20 0.41
CHRM2 P08172 1/20 0.41
ADRA2B P18089 1/20 0.41
DRD3 P35462 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
HRH3 Q9Y5N1 1/20 0.41
SLC6A3 Q01959 4/20 0.40
SLC6A2 P23975 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12602855 0.85 GSK3B (0.46) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA
SCHEMBL19328379 0.83 CES2 (0.45) KMT2AGSK3BCES2CES1MEN1
SCHEMBL5054802 0.82 ALKBH5 (0.47) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA
SCHEMBL5052427 0.81 MMP2 (0.47) KMT2AALDH1A1GSK3BCES2CES1
SCHEMBL5055106 0.81 CYP2C9 (0.51) KMT2AALDH1A1GSK3BLMNACES2
SCHEMBL3110619 0.81 GSK3B (0.48) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA
SCHEMBL12593806 0.81 TDP1 (0.47) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA
SCHEMBL5060223 0.81 ALDH1A1 (0.61) KMT2AALDH1A1GSK3BLMNACES2
SCHEMBL4894019 0.81 GSK3B (0.42) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA
SCHEMBL16922196 0.81 GSK3B (0.42) KMT2AALDH1A1SMN1; SMN2GSK3BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107383005-B Preparation method of 6-methyl-2- (4-methylphenyl) imidazo [1,2-a ] pyridine-3-acetic acid 华东理工大学 2020-03-13 CN claimed
CN-107383005-B Preparation method of 6-methyl-2- (4-methylphenyl) imidazo [1,2-a ] pyridine-3-acetic acid 华东理工大学 2020-03-13 CN disclosed
US-10080757-B2 Inhibitors of UDP-galactopyranose mutase WISCONSIN ALUMNI RESEARCH FOUNDATION 2018-09-25 US disclosed
US-20170258805-A1 INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE WISCONSIN ALUMNI RESEARCH FOUNDATION 2017-09-14 US disclosed
US-20170258805-A1 INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE WISCONSIN ALUMNI RESEARCH FOUNDATION 2017-09-14 US disclosed
US-20170258805-A1 INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE WISCONSIN ALUMNI RESEARCH FOUNDATION 2017-09-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170258805-A1 INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE UGDH, GALE, UGGT1 KMT2A 652/4885ALDH1A1 726/4885SMN1; SMN2 3230/4885
US-10080757-B2 Inhibitors of UDP-galactopyranose mutase UGDH, GALE, UGGT1 KMT2A 652/4885ALDH1A1 726/4885SMN1; SMN2 3230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.